Clayton's Basic Pharmacology for Nurses Comprehensive
Examination Prep Document | 2026/2027 Edition | 150
Verified Questions - 120 Questions with Answers
Clayton's Basic Pharmacology for Nurses Comprehensive Examination 2026-120 QUESTIONS AND ANSWERS
ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously designed for nursing students
preparing for the Clayton's Basic Pharmacology for Nurses Comprehensive Examination in the
2026/2027 academic year. It contains 150 verified questions and answers that cover the entire scope of
basic pharmacology as applied in nursing practice. The content is organized into four core domains,
ensuring thorough coverage of all essential topics. Each question is accompanied by a detailed
rationale, promoting a deep understanding of pharmacological principles and their clinical applications.
This resource is an indispensable tool for achieving a high score and mastering the fundamentals of
pharmacology.
Key Features:
Introduction to Pharmacology: Drug regulation, drug classification, pharmacokinetics, pharmacodynamics, and
adverse drug reactions.
Drug Administration Across the Lifespan: Pediatric, adult, and geriatric considerations, dosage calculations,
and routes of administration.
Medication Safety and Error Prevention: High-alert medications, look-alike/sound-alike drugs, patient
education, and the rights of medication administration.
Autonomic Nervous System Drugs: Cholinergic and adrenergic agonists/antagonists, and their clinical
applications.
Cardiovascular System Drugs: Antihypertensives, antiarrhythmics, inotropes, diuretics, and anticoagulants.
Respiratory System Drugs: Bronchodilators, corticosteroids, expectorants, and antitussives.
Gastrointestinal System Drugs: Antacids, antiemetics, laxatives, antidiarrheals, and drugs for peptic ulcer
disease.
Endocrine System Drugs: Insulin, oral hypoglycemics, thyroid medications, and corticosteroids.
Neurological and Psychiatric Drugs: Anticonvulsants, antipsychotics, antidepressants, and anxiolytics.
Analgesics and Anti-Inflammatory Drugs: Opioids, NSAIDs, acetaminophen, and muscle relaxants.
Antimicrobial Drugs: Antibiotics, antivirals, antifungals, and antituberculars.
Chemotherapy and Immunomodulators: Antineoplastic agents, immunosuppressants, and biologics.
Fluid, Electrolyte, and Acid-Base Balance: IV fluids, electrolytes, and drugs affecting balance.
Herbal and Dietary Supplements: Common interactions and nursing implications.
Professional Responsibilities: Legal and ethical considerations, patient education, and documentation.
Clinical Application and Case Studies: Integrating pharmacology with nursing process and critical thinking.
Updates for 2026:
- Revised to reflect the latest guidelines from the American Nurses Association and the National Council of
State Boards of Nursing.
- Updated drug information includes new FDA approvals and safety alerts as of 2026.
- Enhanced rationales incorporate evidence-based practice and current research findings.
- Added new questions on COVID-19 related therapeutics and vaccines.
- Expanded coverage of opioid safety and pain management protocols.
Page 1
,Abstract:
This exam preparation document is a scholarly resource tailored for nursing students undertaking the Clayton's
Basic Pharmacology for Nurses Comprehensive Examination in the 2026-2027 academic year. It consolidates 150
verified questions and answers into a structured format that mirrors the exam's blueprint, encompassing four core
domains: foundational pharmacology, drug administration and safety, pharmacotherapeutics across body systems,
and professional nursing responsibilities. Each question is crafted to test not only recall but also application,
analysis, and clinical judgment, aligning with the NCLEX-RN and HESI examination frameworks. The document
integrates current pharmacological standards, including updates on drug classifications, mechanisms of action,
therapeutic uses, adverse effects, and nursing interventions. By systematically addressing each domain, it ensures
comprehensive coverage of the syllabus, from basic principles to complex clinical scenarios. The rationales
provided for each answer are detailed, explaining why the correct option is best and why the distractors are
incorrect, thereby reinforcing learning and promoting critical thinking. This resource is an essential tool for exam
success, offering a rigorous review that prepares students to confidently apply pharmacological knowledge in
nursing practice.
Keywords:
Pharmacology for Nurses, NCLEX-RN prep, Drug administration, Nursing exam review, Pharmacotherapeutics,
Medication safety, Clinical pharmacology, 2026-2027 edition
Answer Format:
Each question is presented in a multiple-choice format with four options. The correct answer is indicated, followed
by a comprehensive rationale that explains the underlying pharmacological principles, clinical reasoning, and
nursing implications. Distractor rationales are also provided to clarify common misconceptions and reinforce
learning.
Compliance Checklist:
Aligns with the latest NCLEX-RN test plan and HESI exam blueprint.
Includes evidence-based rationales with citations to standard pharmacology texts.
Covers all four core domains as specified by the College of Nursing.
Updated to reflect 2026-2027 FDA drug approvals and safety alerts.
Designed to promote critical thinking and clinical judgment skills.
Suitable for self-assessment and group study.
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of Pharmacology 1-30 Drug regulation, pharmacokinetics, 20%
pharmacodynamics, adverse drug reactions,
drug interactions
Drug Administration and Safety 31-60 Routes of administration, dosage 20%
calculations, medication errors, patient
education, rights of medication
administration
Pharmacotherapeutics Across 61-120 Autonomic, cardiovascular, respiratory, GI, 40%
Body Systems endocrine, neurological, psychiatric,
analgesic, antimicrobial, chemotherapy
Professional Nursing 121-150 Legal/ethical issues, documentation, patient 20%
Responsibilities education, herbal supplements, clinical case
studies
Page 2
,Q1. A drug has a volume of distribution of 40 L and a clearance of 5 L/hr. If the
target steady-state concentration is 10 mg/L, what is the most appropriate
intravenous maintenance dose (in mg/hr) and loading dose (in mg) respectively?
A. 50 mg/hr and 400 mg
B. 25 mg/hr and 200 mg
C. 50 mg/hr and 200 mg
D. 25 mg/hr and 400 mg
Correct Answer: A. 50 mg/hr and 400 mg
Rationale: Maintenance dose rate = clearance × target concentration = 5 L/hr × 10 mg/L
= 50 mg/hr. Loading dose = Vd × target concentration = 40 L × 10 mg/L = 400 mg. Thus,
option A is correct. The other options either halve or swap the values incorrectly.
Why Wrong:
B - This option halves the maintenance dose and loading dose incorrectly.
C - This option has the correct maintenance but the loading dose is halved.
D - This option has the correct loading dose but the maintenance dose is halved.
Reference: Clayton, B.D., & Stock, Y.N. (2026). Basic Pharmacology for Nurses, 19th Ed.,
Ch. 3
Q2. Which drug-receptor interaction is most likely to produce a ceiling effect with
increasing doses, and why?
A. Noncompetitive antagonist, because it irreversibly blocks the receptor
B. Partial agonist, because it has lower intrinsic efficacy than a full agonist
C. Competitive antagonist, because it can be overcome by increasing agonist
concentration
D. Allosteric modulator, because it changes receptor conformation but not the agonist
binding site
Correct Answer: B. Partial agonist, because it has lower intrinsic efficacy than a full
agonist
Rationale: A partial agonist produces a submaximal response even at full receptor
occupancy, leading to a ceiling effect. Noncompetitive antagonists reduce the maximum
response but do not produce a ceiling effect themselves; competitive antagonists can be
overcome; allosteric modulators may enhance or inhibit but do not directly produce a
ceiling effect.
Why Wrong:
A - Noncompetitive antagonists reduce the maximal effect but do not have a ceiling
effect of their own.
C - Competitive antagonists shift the dose-response curve rightward without a ceiling
effect.
D - Allosteric modulators do not directly produce a ceiling effect; they modulate the
Page 3
, response to the agonist.
Reference: Clayton, B.D., & Stock, Y.N. (2026). Basic Pharmacology for Nurses, 19th Ed.,
Ch. 2
Q3. A patient on an SSRI is prescribed linezolid. Which adverse effect is of greatest
concern, and what is the underlying mechanism?
A. Hypertensive crisis due to monoamine oxidase inhibition
B. Serotonin syndrome due to excessive serotonergic activity
C. QT prolongation due to additive effects on cardiac potassium channels
D. Bone marrow suppression due to synergistic myelotoxicity
Correct Answer: B. Serotonin syndrome due to excessive serotonergic activity
Rationale: Linezolid is a weak, reversible MAO inhibitor. Combining it with an SSRI
increases serotonin levels dangerously, leading to serotonin syndrome. Hypertensive crisis
is more associated with tyramine-rich foods, not SSRIs. QT prolongation and bone
marrow suppression are not the primary concern with this combination.
Why Wrong:
A - Hypertensive crisis is a risk with MAOIs and tyramine, but the main interaction
with SSRIs is serotonin syndrome.
C - QT prolongation is not the primary interaction between linezolid and SSRIs.
D - Bone marrow suppression is a concern with linezolid alone but not the primary
interaction with SSRIs.
Reference: Clayton, B.D., & Stock, Y.N. (2026). Basic Pharmacology for Nurses, 19th Ed.,
Ch. 42
Q4. A patient with chronic heart failure is on digoxin and furosemide. Which
electrolyte imbalance increases the risk of digoxin toxicity, and what is the primary
mechanism?
A. Hyperkalemia, which displaces digoxin from Na+/K+-ATPase
B. Hypokalemia, which enhances digoxin binding to Na+/K+-ATPase
C. Hypomagnesemia, which reduces digoxin clearance
D. Hypercalcemia, which potentiates the inotropic effect of digoxin
Correct Answer: B. Hypokalemia, which enhances digoxin binding to
Na+/K+-ATPase
Rationale: Hypokalemia increases the binding of digoxin to Na+/K+-ATPase, enhancing
its toxic effects. Hyperkalemia actually reduces digoxin binding. Hypomagnesemia may
also increase toxicity, but the primary mechanism is hypokalemia. Hypercalcemia can
increase digoxin effects but is not the primary concern with furosemide.
Why Wrong:
A - Hyperkalemia reduces digoxin binding, not increases toxicity.
Page 4
Examination Prep Document | 2026/2027 Edition | 150
Verified Questions - 120 Questions with Answers
Clayton's Basic Pharmacology for Nurses Comprehensive Examination 2026-120 QUESTIONS AND ANSWERS
ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously designed for nursing students
preparing for the Clayton's Basic Pharmacology for Nurses Comprehensive Examination in the
2026/2027 academic year. It contains 150 verified questions and answers that cover the entire scope of
basic pharmacology as applied in nursing practice. The content is organized into four core domains,
ensuring thorough coverage of all essential topics. Each question is accompanied by a detailed
rationale, promoting a deep understanding of pharmacological principles and their clinical applications.
This resource is an indispensable tool for achieving a high score and mastering the fundamentals of
pharmacology.
Key Features:
Introduction to Pharmacology: Drug regulation, drug classification, pharmacokinetics, pharmacodynamics, and
adverse drug reactions.
Drug Administration Across the Lifespan: Pediatric, adult, and geriatric considerations, dosage calculations,
and routes of administration.
Medication Safety and Error Prevention: High-alert medications, look-alike/sound-alike drugs, patient
education, and the rights of medication administration.
Autonomic Nervous System Drugs: Cholinergic and adrenergic agonists/antagonists, and their clinical
applications.
Cardiovascular System Drugs: Antihypertensives, antiarrhythmics, inotropes, diuretics, and anticoagulants.
Respiratory System Drugs: Bronchodilators, corticosteroids, expectorants, and antitussives.
Gastrointestinal System Drugs: Antacids, antiemetics, laxatives, antidiarrheals, and drugs for peptic ulcer
disease.
Endocrine System Drugs: Insulin, oral hypoglycemics, thyroid medications, and corticosteroids.
Neurological and Psychiatric Drugs: Anticonvulsants, antipsychotics, antidepressants, and anxiolytics.
Analgesics and Anti-Inflammatory Drugs: Opioids, NSAIDs, acetaminophen, and muscle relaxants.
Antimicrobial Drugs: Antibiotics, antivirals, antifungals, and antituberculars.
Chemotherapy and Immunomodulators: Antineoplastic agents, immunosuppressants, and biologics.
Fluid, Electrolyte, and Acid-Base Balance: IV fluids, electrolytes, and drugs affecting balance.
Herbal and Dietary Supplements: Common interactions and nursing implications.
Professional Responsibilities: Legal and ethical considerations, patient education, and documentation.
Clinical Application and Case Studies: Integrating pharmacology with nursing process and critical thinking.
Updates for 2026:
- Revised to reflect the latest guidelines from the American Nurses Association and the National Council of
State Boards of Nursing.
- Updated drug information includes new FDA approvals and safety alerts as of 2026.
- Enhanced rationales incorporate evidence-based practice and current research findings.
- Added new questions on COVID-19 related therapeutics and vaccines.
- Expanded coverage of opioid safety and pain management protocols.
Page 1
,Abstract:
This exam preparation document is a scholarly resource tailored for nursing students undertaking the Clayton's
Basic Pharmacology for Nurses Comprehensive Examination in the 2026-2027 academic year. It consolidates 150
verified questions and answers into a structured format that mirrors the exam's blueprint, encompassing four core
domains: foundational pharmacology, drug administration and safety, pharmacotherapeutics across body systems,
and professional nursing responsibilities. Each question is crafted to test not only recall but also application,
analysis, and clinical judgment, aligning with the NCLEX-RN and HESI examination frameworks. The document
integrates current pharmacological standards, including updates on drug classifications, mechanisms of action,
therapeutic uses, adverse effects, and nursing interventions. By systematically addressing each domain, it ensures
comprehensive coverage of the syllabus, from basic principles to complex clinical scenarios. The rationales
provided for each answer are detailed, explaining why the correct option is best and why the distractors are
incorrect, thereby reinforcing learning and promoting critical thinking. This resource is an essential tool for exam
success, offering a rigorous review that prepares students to confidently apply pharmacological knowledge in
nursing practice.
Keywords:
Pharmacology for Nurses, NCLEX-RN prep, Drug administration, Nursing exam review, Pharmacotherapeutics,
Medication safety, Clinical pharmacology, 2026-2027 edition
Answer Format:
Each question is presented in a multiple-choice format with four options. The correct answer is indicated, followed
by a comprehensive rationale that explains the underlying pharmacological principles, clinical reasoning, and
nursing implications. Distractor rationales are also provided to clarify common misconceptions and reinforce
learning.
Compliance Checklist:
Aligns with the latest NCLEX-RN test plan and HESI exam blueprint.
Includes evidence-based rationales with citations to standard pharmacology texts.
Covers all four core domains as specified by the College of Nursing.
Updated to reflect 2026-2027 FDA drug approvals and safety alerts.
Designed to promote critical thinking and clinical judgment skills.
Suitable for self-assessment and group study.
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of Pharmacology 1-30 Drug regulation, pharmacokinetics, 20%
pharmacodynamics, adverse drug reactions,
drug interactions
Drug Administration and Safety 31-60 Routes of administration, dosage 20%
calculations, medication errors, patient
education, rights of medication
administration
Pharmacotherapeutics Across 61-120 Autonomic, cardiovascular, respiratory, GI, 40%
Body Systems endocrine, neurological, psychiatric,
analgesic, antimicrobial, chemotherapy
Professional Nursing 121-150 Legal/ethical issues, documentation, patient 20%
Responsibilities education, herbal supplements, clinical case
studies
Page 2
,Q1. A drug has a volume of distribution of 40 L and a clearance of 5 L/hr. If the
target steady-state concentration is 10 mg/L, what is the most appropriate
intravenous maintenance dose (in mg/hr) and loading dose (in mg) respectively?
A. 50 mg/hr and 400 mg
B. 25 mg/hr and 200 mg
C. 50 mg/hr and 200 mg
D. 25 mg/hr and 400 mg
Correct Answer: A. 50 mg/hr and 400 mg
Rationale: Maintenance dose rate = clearance × target concentration = 5 L/hr × 10 mg/L
= 50 mg/hr. Loading dose = Vd × target concentration = 40 L × 10 mg/L = 400 mg. Thus,
option A is correct. The other options either halve or swap the values incorrectly.
Why Wrong:
B - This option halves the maintenance dose and loading dose incorrectly.
C - This option has the correct maintenance but the loading dose is halved.
D - This option has the correct loading dose but the maintenance dose is halved.
Reference: Clayton, B.D., & Stock, Y.N. (2026). Basic Pharmacology for Nurses, 19th Ed.,
Ch. 3
Q2. Which drug-receptor interaction is most likely to produce a ceiling effect with
increasing doses, and why?
A. Noncompetitive antagonist, because it irreversibly blocks the receptor
B. Partial agonist, because it has lower intrinsic efficacy than a full agonist
C. Competitive antagonist, because it can be overcome by increasing agonist
concentration
D. Allosteric modulator, because it changes receptor conformation but not the agonist
binding site
Correct Answer: B. Partial agonist, because it has lower intrinsic efficacy than a full
agonist
Rationale: A partial agonist produces a submaximal response even at full receptor
occupancy, leading to a ceiling effect. Noncompetitive antagonists reduce the maximum
response but do not produce a ceiling effect themselves; competitive antagonists can be
overcome; allosteric modulators may enhance or inhibit but do not directly produce a
ceiling effect.
Why Wrong:
A - Noncompetitive antagonists reduce the maximal effect but do not have a ceiling
effect of their own.
C - Competitive antagonists shift the dose-response curve rightward without a ceiling
effect.
D - Allosteric modulators do not directly produce a ceiling effect; they modulate the
Page 3
, response to the agonist.
Reference: Clayton, B.D., & Stock, Y.N. (2026). Basic Pharmacology for Nurses, 19th Ed.,
Ch. 2
Q3. A patient on an SSRI is prescribed linezolid. Which adverse effect is of greatest
concern, and what is the underlying mechanism?
A. Hypertensive crisis due to monoamine oxidase inhibition
B. Serotonin syndrome due to excessive serotonergic activity
C. QT prolongation due to additive effects on cardiac potassium channels
D. Bone marrow suppression due to synergistic myelotoxicity
Correct Answer: B. Serotonin syndrome due to excessive serotonergic activity
Rationale: Linezolid is a weak, reversible MAO inhibitor. Combining it with an SSRI
increases serotonin levels dangerously, leading to serotonin syndrome. Hypertensive crisis
is more associated with tyramine-rich foods, not SSRIs. QT prolongation and bone
marrow suppression are not the primary concern with this combination.
Why Wrong:
A - Hypertensive crisis is a risk with MAOIs and tyramine, but the main interaction
with SSRIs is serotonin syndrome.
C - QT prolongation is not the primary interaction between linezolid and SSRIs.
D - Bone marrow suppression is a concern with linezolid alone but not the primary
interaction with SSRIs.
Reference: Clayton, B.D., & Stock, Y.N. (2026). Basic Pharmacology for Nurses, 19th Ed.,
Ch. 42
Q4. A patient with chronic heart failure is on digoxin and furosemide. Which
electrolyte imbalance increases the risk of digoxin toxicity, and what is the primary
mechanism?
A. Hyperkalemia, which displaces digoxin from Na+/K+-ATPase
B. Hypokalemia, which enhances digoxin binding to Na+/K+-ATPase
C. Hypomagnesemia, which reduces digoxin clearance
D. Hypercalcemia, which potentiates the inotropic effect of digoxin
Correct Answer: B. Hypokalemia, which enhances digoxin binding to
Na+/K+-ATPase
Rationale: Hypokalemia increases the binding of digoxin to Na+/K+-ATPase, enhancing
its toxic effects. Hyperkalemia actually reduces digoxin binding. Hypomagnesemia may
also increase toxicity, but the primary mechanism is hypokalemia. Hypercalcemia can
increase digoxin effects but is not the primary concern with furosemide.
Why Wrong:
A - Hyperkalemia reduces digoxin binding, not increases toxicity.
Page 4
